-
Je něco špatně v tomto záznamu ?
Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells
T. Muchova, J. Pracharova, P. Starha, R. Olivova, O. Vrana, B. Benesova, J. Kasparkova, Z. Travnicek, V. Brabec,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- apoptóza účinky léků MeSH
- buněčný cyklus účinky léků MeSH
- glutathion chemie MeSH
- lidé MeSH
- nádorové buněčné linie MeSH
- oprava DNA MeSH
- organoplatinové sloučeniny chemie toxicita MeSH
- poškození DNA účinky léků MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
The cisplatin analogues cis-[PtCl2(3ClHaza)2] (1) and cis-[PtCl2(3IHaza)2] (2) (3ClHaza and 3IHaza are 3-chloro-7-azaindole and 3-iodo-7-azaindole, respectively) are quite toxic to ovarian tumor cells, with moderately better IC50 values than for cisplatin in the cisplatin-sensitive cell line A2780. We investigated potential factors which might be involved in the mechanism underlying the cytotoxic effects of 1 and 2 and compared these factors with those involved in the mechanism underlying the effects of conventional cisplatin. Our data indicate that the higher cytotoxicity of 1 and 2 originates mainly from their efficient cellular accumulation, different effects at the level of cell cycle regulation, and reduced propensity for DNA adduct repair. Studies of their reactivity toward cellular components reveal efficient binding to DNA, which is typically required for an active platinum drug. Further results suggest that 1 and 2 are capable of circumventing resistance to cisplatin induced by alterations in cellular accumulation and DNA repair. Hence, the latter two factors appear to be responsible for differences in the toxicity of 1 or 2, and cisplatin in tumor cells. The results of this work reinforce the idea that direct analogues of conventional cisplatin-containing halogeno-substituted 7-azaindoles offer much promise for the design of novel therapeutic agents.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc14040742
- 003
- CZ-PrNML
- 005
- 20140114114554.0
- 007
- ta
- 008
- 140107s2013 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00775-013-1003-7 $2 doi
- 035 __
- $a (PubMed)23674329
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Muchova, Tereza
- 245 10
- $a Insight into the toxic effects of cis-dichloridoplatinum(II) complexes containing 7-azaindole halogeno derivatives in tumor cells / $c T. Muchova, J. Pracharova, P. Starha, R. Olivova, O. Vrana, B. Benesova, J. Kasparkova, Z. Travnicek, V. Brabec,
- 520 9_
- $a The cisplatin analogues cis-[PtCl2(3ClHaza)2] (1) and cis-[PtCl2(3IHaza)2] (2) (3ClHaza and 3IHaza are 3-chloro-7-azaindole and 3-iodo-7-azaindole, respectively) are quite toxic to ovarian tumor cells, with moderately better IC50 values than for cisplatin in the cisplatin-sensitive cell line A2780. We investigated potential factors which might be involved in the mechanism underlying the cytotoxic effects of 1 and 2 and compared these factors with those involved in the mechanism underlying the effects of conventional cisplatin. Our data indicate that the higher cytotoxicity of 1 and 2 originates mainly from their efficient cellular accumulation, different effects at the level of cell cycle regulation, and reduced propensity for DNA adduct repair. Studies of their reactivity toward cellular components reveal efficient binding to DNA, which is typically required for an active platinum drug. Further results suggest that 1 and 2 are capable of circumventing resistance to cisplatin induced by alterations in cellular accumulation and DNA repair. Hence, the latter two factors appear to be responsible for differences in the toxicity of 1 or 2, and cisplatin in tumor cells. The results of this work reinforce the idea that direct analogues of conventional cisplatin-containing halogeno-substituted 7-azaindoles offer much promise for the design of novel therapeutic agents.
- 650 _2
- $a apoptóza $x účinky léků $7 D017209
- 650 _2
- $a buněčný cyklus $x účinky léků $7 D002453
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a poškození DNA $x účinky léků $7 D004249
- 650 _2
- $a oprava DNA $7 D004260
- 650 _2
- $a glutathion $x chemie $7 D005978
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a organoplatinové sloučeniny $x chemie $x toxicita $7 D009944
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Pracharova, Jitka $u -
- 700 1_
- $a Starha, Pavel $u -
- 700 1_
- $a Olivova, Radana $u -
- 700 1_
- $a Vrana, Oldrich $u -
- 700 1_
- $a Benesova, Barbora $u -
- 700 1_
- $a Kasparkova, Jana $u -
- 700 1_
- $a Travnicek, Zdenek $u -
- 700 1_
- $a Brabec, Viktor $u -
- 773 0_
- $w MED00005752 $t Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry $x 1432-1327 $g Roč. 18, č. 5 (2013), s. 579-89
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23674329 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20140107 $b ABA008
- 991 __
- $a 20140114115258 $b ABA008
- 999 __
- $a ok $b bmc $g 1005138 $s 839254
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 18 $c 5 $d 579-89 $i 1432-1327 $m JBIC, Journal of biological inorganic chemistry $n J Biol Inorg Chem $x MED00005752
- LZP __
- $a Pubmed-20140107